Liu CJ - Search Results

1

Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan.

Cheng PN, Chen CY, Yu ML, Lin CC, Lin CY, Peng CY, Tseng KC, Lo CC, Tseng IH, Liu CJ. Cheng PN, et al. Among authors: liu cj. J Microbiol Immunol Infect. 2021 Aug;54(4):588-595. doi: 10.1016/j.jmii.2020.05.004. Epub 2020 May 22. J Microbiol Immunol Infect. 2021. PMID: 32499107 Free article.

2

Mapping of DNA markers to arms and sub-arm regions of Nicotiana sylvestris chromosomes using aberrant alien addition lines.

Chen C, Chen K, Liu C, Kao Y. Chen C, et al. Theor Appl Genet. 2002 Jul;105(1):8-15. doi: 10.1007/s00122-001-0829-5. Epub 2002 May 18. Theor Appl Genet. 2002. PMID: 12582556

3

Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C.

Liu CJ, Jeng YM, Chen PJ, Lai MY, Yang HC, Huang WL, Kao JH, Chen DS. Liu CJ, et al. Antivir Ther. 2005;10(3):405-15. Antivir Ther. 2005. PMID: 15918331

4

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, Hsu CS, Tseng TC, Wang CC, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH. Liu CH, et al. Among authors: liu cj. Clin Infect Dis. 2008 Nov 15;47(10):1260-9. doi: 10.1086/592579. Clin Infect Dis. 2008. PMID: 18834319 Clinical Trial.

5

Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.

Liu CJ, Chuang WL, Lee CM, Yu ML, Lu SN, Wu SS, Liao LY, Chen CL, Kuo HT, Chao YC, Tung SY, Yang SS, Kao JH, Liu CH, Su WW, Lin CL, Jeng YM, Chen PJ, Chen DS. Liu CJ, et al. Among authors: liu ch. Gastroenterology. 2009 Feb;136(2):496-504.e3. doi: 10.1053/j.gastro.2008.10.049. Epub 2008 Oct 29. Gastroenterology. 2009. PMID: 19084016 Clinical Trial.

6

Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage.

Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Lee CC, Yu MC, Hu RH, Peng CY, Lai KL, Chang SS, Chen PJ. Liu CJ, et al. J Hepatol. 2009 May;50(5):958-68. doi: 10.1016/j.jhep.2008.12.023. Epub 2009 Feb 15. J Hepatol. 2009. PMID: 19303160 Clinical Trial.

7

HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.

Yu ML, Lee CM, Chuang WL, Lu SN, Dai CY, Huang JF, Lin ZY, Hu TH, Chen CH, Hung CH, Wang JH, Chen CL, Kao JH, Lai MY, Liu CH, Su TH, Wu SS, Liao LY, Kuo HT, Chao YC, Tung SY, Yang SS, Chen PJ, Liu CJ, Chen DS. Yu ML, et al. Among authors: liu ch, liu cj. J Infect Dis. 2010 Jul 1;202(1):86-92. doi: 10.1086/653209. J Infect Dis. 2010. PMID: 20482252

8

Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.

Yeh ML, Hung CH, Huang JF, Liu CJ, Lee CM, Dai CY, Wang JH, Lin ZY, Lu SN, Hu TH, Yu ML, Kao JH, Chuang WL, Chen PJ, Chen DS. Yeh ML, et al. Among authors: liu cj. PLoS One. 2011;6(6):e20752. doi: 10.1371/journal.pone.0020752. Epub 2011 Jun 13. PLoS One. 2011. PMID: 21695152 Free PMC article. Clinical Trial.

9

Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.

Tseng TC, Yu ML, Liu CJ, Lin CL, Huang YW, Hsu CS, Liu CH, Kuo SF, Pan CJ, Yang SS, Su CW, Chen PJ, Chen DS, Kao JH. Tseng TC, et al. Among authors: liu ch, liu cj. Antivir Ther. 2011;16(5):629-37. doi: 10.3851/IMP1841. Antivir Ther. 2011. PMID: 21817184

10

Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.

Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, Su TH, Hsu SJ, Lin JW, Chen JH, Chen PJ, Chen DS, Kao JH. Liu CH, et al. Among authors: liu cj. Antivir Ther. 2012;17(3):477-84. doi: 10.3851/IMP2026. Epub 2011 Dec 20. Antivir Ther. 2012. PMID: 22301466 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,172 results

Search Page